Webtable 3

Summary of the results derived from the five different analytical strategies analyzing the hazard of functional graft loss in the AZA vs MMF patients adjusted for several covariables.

Parameter	Hazard Ratio	95% confidence interval		p-value
Complete case only (N=815, 62 events)				
AZA vs. MMF	2.15	1.16	4.02	0.016
Sum of HLA mismatch	1.21	1.00	1.45	0.046
Time on dialysis	1.14	1.00	1.29	0.042
MAP	1.01	1.00	1.02	0.002
CNI use	2.43	0.98	6.01	0.056
Steroid use	0.45	0.19	1.11	0.084
Multiple imputation (N=1219, 116 events)				
AZA vs. MMF	2.01	1.24	3.26	0.005
Sum of HLA mismatch	1.24	1.07	1.45	0.006
Time on dialysis	1.14	1.05	1.23	0.001
Cardiomyopathy	1.85	0.83	4.16	0.122
MAP	1.01	1.00	1.02	0.042
Cholesterol	0.99	0.99	1.00	0.002
Coronary heart disease	1.44	0.86	2.39	0.162
CNI use	1.66	0.96	2.86	0.070
Steroid use	0.59	0.35	1.01	0.054
Multiple imputation analysis, follow-up>1 year (N=948, 63 events)				
AZA vs. MMF	1.25	0.60	2.64	0.552
Sum of HLA mismatch	1.17	0.97	1.42	0.099
Time on dialysis	1.13	0.99	1.29	0.070
Cardiomyopathy	1.36	0.42	4.36	0.577
MAP	1.01	1.00	1.02	0.018
Cholesterol	1.00	0.99	1.00	0.087
Coronary heart disease	1.41	0.71	2.81	0.325
CNI use	0.56	0.23	1.38	0.206
Steroid use	1.26	0.51	3.07	0.619

Parameter	Hazard Ratio	95% confidence interval		p-value
Inverse probability of received treatment weighting (MSM)				
AZA vs. MMF	1.97	0.70	5.51	0.197
Propensity score model				
AZA vs. MMF	1.47	0.89	2.42	0.132
propensity	0.12	0.05	0.30	<0.001